MaaT Pharma: Clinical Trials

5 trials sponsored by MaaT Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 1 terminated. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Recruiting 2, Terminated 1
Phase 11Completed 1

Follow MaaT Pharma: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer
MaaT033 capsule, Cemiplimab, Cisplatin - NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris1622025-11-172026-04-03
Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
Pooled allogeneic fecal microbiotherapy, Placebo - Transplant Complication
Phase 2RecruitingMaaT Pharma3872023-10-312024-12-27
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer
fecal microbiota transfer - Fecal Microbiota Transplantation
Phase 2CompletedMaaT Pharma242018-08-132021-02-23
Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY
fecal microbiota transfer - Intensive Care Units, Fecal Microbiota Transplantation
Phase 2TerminatedMaaT Pharma82018-01-152019-03-08
PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients
Autologous Fecal Microbiota Transplantation - Leukemia, Myeloid, Acute
Phase 1 / Phase 2CompletedMaaT Pharma202016-06-012020-09-09

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Leukemia, Myeloid, Acute (1)

Interventions

Fecal Microbiota Transplantation (2)  ·  Bevacizumab (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Docetaxel (1)  ·  Gemcitabine (1)  ·  Paclitaxel (1)  ·  Pemetrexed (1)  ·  Vinorelbine (1)  ·  cemiplimab (1)

Countries

France (5)  ·  Belgium (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Florent Malard, MD, PhD (2)  ·  Anahita Rouze (1)  ·  Mohamad Mohty, MD, PhD (1)

Results publications

PMID 34035290, PMID 37654670